Cancer‐associated point mutations within the extracellular domain of PTPRD affect protein stability and HSPG interaction
The FASEB Journal · 2024
DOI: 10.1096/fj.202302279rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Yu Matsui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine, University of Toyama, Toyama, Japan. Hauptthemen laut MEDLINE: Heparan Sulfate Proteoglycans, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), Japan Society for the Promotion of Science.
Abstract (Originalsprache)
PTPRD , a well‐established tumor suppressor gene, encodes the protein tyrosine phosphatase‐type D. This protein consists of three immunoglobulin‐like (Ig) domains, four to eight fibronectin type 3 (FN) domains, a single transmembrane segment, and two cytoplasmic tandem tyrosine phosphatase domains. PTPRD is known to harbor various cancer‐associated point mutations. While it is assumed that PTPRD regulates cellular functions as a tumor suppressor through the tyrosine phosphatase activity in the intracellular region, the function of its extracellular domain (ECD) in cancer is not well understood. In this study, we systematically examined the impact of 92 cancer‐associated point mutations within the ECD. We found that 69.6% (64 out of 92) of these mutations suppressed total protein expression and/or plasma membrane localization. Notably, almost all mutations (20 out of 21) within the region between the last FN domain and transmembrane segment affected protein expression and/or localization, highlighting the importance of this region for protein stability. We further found that some mutations within the Ig domains adjacent to the glycosaminoglycan‐binding pocket enhanced PTPRD's binding ability to heparan sulfate proteoglycans (HSPGs). This interaction is proposed to suppress phosphatase activity. Our findings therefore suggest that HSPG‐mediated attenuation of phosphatase activity may be involved in tumorigenic processes through PTPRD dysregulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine, University of Toyama, Toyama, Japan.
- Department of Molecular Neuroscience, Faculty of Medicine, University of Toyama, Toyama, Japan.
- Research Center for Idling Brain Science, University of Toyama, Toyama, Japan.
- Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Division of Developmental Neuroscience, United Graduate School of Child Development (UGSCD), Osaka University, Osaka, Japan.
ORCID-Profile: Yu Matsui, Ayako Imai, Hironori Izumi, Misato Yasumura, Teruhiko Makino, Tadamichi Shimizu, Makoto Sato, Hisashi Mori, Tomoyuki Yoshida
Förderung
- MEXT | Japan Society for the Promotion of Science (JSPS)
- Japan Society for the Promotion of Science
Zitieren
APA
Matsui, Y., Imai, A., Izumi, H., Yasumura, M., Makino, T., Shimizu, T., Sato, M., Mori, H., & Yoshida, T. (2024). Cancer‐associated point mutations within the extracellular domain of PTPRD affect protein stability and HSPG interaction. The FASEB Journal. https://doi.org/10.1096/fj.202302279rr
Vancouver
Matsui Y, Imai A, Izumi H, Yasumura M, Makino T, Shimizu T, et al. Cancer‐associated point mutations within the extracellular domain of PTPRD affect protein stability and HSPG interaction. The FASEB Journal. 2024. doi:10.1096/fj.202302279rr
BibTeX
@article{Matsui2024,
author = {Matsui, Yu and Imai, Ayako and Izumi, Hironori and Yasumura, Misato and Makino, Teruhiko and Shimizu, Tadamichi and Sato, Makoto and Mori, Hisashi and Yoshida, Tomoyuki},
title = {Cancer‐associated point mutations within the extracellular domain of PTPRD affect protein stability and HSPG interaction},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202302279rr}
}
EUVIMED